ArticleInfection and immunity2002
Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System.Journal of fungi (Basel, Switzerland) · 2025Article
- From soil to clinic: current advances in understandingMicrobiology and molecular biology reviews : MMBR · 2024Review
- Outcomes with severe pulmonary coccidioidomycosis and respiratory failure in the United States.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2023Article
- Modeling Chronic Coccidioidomycosis in Mice.Methods in molecular biology (Clifton, N.J.) · 2023Article
- A chromosomal-level reference genome of the widely utilized Coccidioides posadasii laboratory strain "Silveira".G3 (Bethesda, Md.) · 2022Article
- The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen Coccidioides posadasii.PLoS pathogens · 2022Article
- Coccidioidomycosis: Changing Concepts and Knowledge Gaps.Journal of fungi (Basel, Switzerland) · 2020Review
- Host Response toFrontiers in cellular and infection microbiology · 2020Review
- The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis.Virulence · 2019Review
- Viable spores of Coccidioides posadasii Δcps1 are required for vaccination and provide long lasting immunity.Vaccine · 2018Article
- Immune Response to Coccidioidomycosis and the Development of a Vaccine.Microorganisms · 2017Review
- A Coccidioides posadasii CPS1 Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection.Infection and immunity · 2016Article
- Dust devil: the life and times of the fungus that causes valley Fever.PLoS pathogens · 2015Review
- Article
- An insight into the antifungal pipeline: selected new molecules and beyond.Nature reviews. Drug discovery · 2010Review
- What's Behind the Increasing Rates of Coccidioidomycosis in Arizona and California?Current infectious disease reports · 2010Article
- Polyfunctional T lymphocytes are in the peripheral blood of donors naturally immune to coccidioidomycosis and are not induced by dendritic cells.Infection and immunity · 2010Article
- Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.Infection and immunity · 2007Article
- Efficacy of ambruticin analogs in a murine model of coccidioidomycosis.Antimicrobial agents and chemotherapy · 2006Article
- Novel approach to designing primers for identification and distinction of the human pathogenic fungi Coccidioides immitis and Coccidioides posadasii by PCR amplification.Journal of clinical microbiology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Subcutaneous vaccination with recombinant antigen 2/PRA (rAg2/PRA) protected BALB/c mice against intranasal infection with Coccidioides immitis. Subcutaneously vaccinated C57BL/6 mice and intranasally vaccinated BALB/c mice were protected against larger numbers of infecting spores. Weight loss correlated with lethality, but histologic appearance did not. These studies support rAg2/PRA vaccination to prevent coccidioidomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.